Generate Biomedicines and Zealand Pharma signed a deal worth up to $1.2 billion to design AI-generated multispecific protein therapeutics for obesity, marking Zealand's first move beyond peptide-based drugs.
A JAMA Network Open study of nearly 1,565 physicians found AI scribe adopters generated 1.81 more RVUs per week and about $3,044 more annual revenue than non-adopters, with no increase in claim denials.
UpDoc revealed that the FDA cleared its patient-facing LLM-based insulin management software back in December 2025, months before announcing it alongside pilot programs at Cleveland Clinic, Allegheny Health Network, and UCSF Health.
A JMIR Mental Health pilot trial found only 39% of users completed a purpose-built AI therapy chatbot program, versus 62% who stuck with plain ChatGPT, raising new questions about engagement in AI mental-health tools.
Anthropic has reportedly agreed to acquire stealth drug-discovery startup Coefficient Bio in a $400 million all-stock deal, deepening its push into life sciences alongside a wave of AI-pharma tie-ups.
A new British Journal of Dermatology study of the SkinVision app found strong accuracy when clinicians captured images but a sharp drop-off when patients photographed their own skin, while a separate Dutch study of 2.2 million users found big jumps in both cancer detection and false-positive referrals.
Mass General Brigham has deployed an AI intake agent inside MyChart to handle primary care pre-visit assessments, part of a broader push by hospital systems and EHR vendors like Epic to automate administrative work ahead of appointments.
A Harvard-linked analysis of physician queries to the clinical AI tool OpenEvidence found doctors mainly use AI to inform treatment and management decisions rather than diagnosis, a pattern mirrored in how Epic and Doximity are building their own clinical AI tools.
The American Hospital Association urged the FDA to adopt flexible, risk-based oversight of generative AI medical tools as the agency's comment period on its discussion paper closed October 19, with patient-safety advocates pushing for firmer rules instead.
The UK's MHRA unveiled a 2030 regulatory strategy built around AI and personalised medicine, promising faster trial reviews, a new AI and Digital Health centre, and closer alignment with the FDA on device recognition.